Similarly, no significance was achieved in stimulated C-peptide, HbA1c, insulin demand, and hypoglycemia rate was achieved in a phase 3 study on 327 recent-onset patients between 10 and 20 years of age (4-dose regimen GAD65 Alum: 111 patients, 2-dose regimen GAD65 Alum: 108 patients, placebo: 115 patients; Ludvigsson et al, 2012). Here, GAD2 is linked to Hypoglycemia.